Life Sciences Times, Author at Boston Life Sciences Times

Casma Therapeutics Secures $7.6 Million in MJFF Funding to Advance Parkinson’s Disease Program

March 10, 2026

NEJM Publishes Data Suggesting Zorevunersen May Modify Disease Course in Dravet Syndrome

March 5, 2026

Arsenal Medical Treats First Patient with ResQFoam Device for Life-Threatening Abdominal Bleeding

March 4, 2026

THIS WEEK'S STORIES

Odyssey Therapeutics Appoints H. Martin Seidel, Ph.D., to Scientific Advisory Board

March 10, 2026

Cognito Therapeutics Names Thomas Fagan Executive Vice President of Alzheimer’s Portfolio

March 11, 2026

Response Pharmaceuticals Reports Positive Phase 2 Data for RDX-002 in Post-GLP-1 Weight Management

March 5, 2026

ABOUT US

Life Science Times is New England’s premier life sciences publication, covering the Pharma, Biotech, MedTech and Public Health sectors nationwide with a special focus on New England. Updated daily, we cover the latest news in everything else that touches any rubric of the rapidly growing life sciences industry.

Life Sciences Times

TOP AUTHORS

Most Read

Aurion Biotech Names Marjan Farid, M.D., Chair of Medical Advisory Board

Parabilis Medicines’ Zolucatetide Receives FDA Orphan Drug Designation for Desmoid Tumors

GelMEDIX, Catalent Partner to Develop Stem Cell-Based Therapies for Ocular and Retinal Diseases

Cognito Therapeutics Names Thomas Fagan Executive Vice President of Alzheimer’s Portfolio

EDITOR PICKS

Casma Therapeutics Secures $7.6 Million in MJFF Funding to Advance Parkinson’s Disease Program

NEJM Publishes Data Suggesting Zorevunersen May Modify Disease Course in Dravet Syndrome

Arsenal Medical Treats First Patient with ResQFoam Device for Life-Threatening Abdominal Bleeding

THIS WEEK'S STORIES

Odyssey Therapeutics Appoints H. Martin Seidel, Ph.D., to Scientific Advisory Board

Cognito Therapeutics Names Thomas Fagan Executive Vice President of Alzheimer’s Portfolio

Response Pharmaceuticals Reports Positive Phase 2 Data for RDX-002 in Post-GLP-1 Weight Management

POPULAR CATEGORY

ABOUT US

FOLLOW US